Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis.

Trial Profile

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Ponesimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2013 Planned number of patients changed from 400 to 460 as reported by European Clinical Trials Database. (Parent trial: EudraCT2008-006786-92).
    • 13 Oct 2012 Results of MRI-assessed endpoints presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 13 Oct 2012 Results, including pharmacodynamic outcomes, presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top